Results 151 to 160 of about 9,256,185 (298)

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Clinical and genetic characterization of X-linked agammaglobulinemia in a Colombian cohort. [PDF]

World Allergy Organ J
Olaya Hernández M, Triviño Arias J, Arias Valderrama O, Cabrera Guarín V, Patiño JA, Pachajoa HM, Valencia DM, Franco AA, Castaño Jaramillo LM, Vélez Tirado N, Zea-Vera AF, Ortega-López MC, Olmos-Olmos C, Arévalo-Montenegro Y, Rincón-Arenas L, Franco JL, Orrego JC, Vásquez E, Obando-Gil C, Moribe I, Valderrama ML, Gómez-Parada C, Álvarez M, Arias AF, Pérez PM, Correa Jiménez O.   +25 more
europepmc   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

X-linked hypophosphatemic rickets: case report with perspectives and challenges. [PDF]

Einstein (Sao Paulo)
Ribeiro BA, Soga HM, Lima FT, Ramalho Júnior A, Nascimento CGS, Troster EJ, Vieira TCGA.   +6 more
europepmc   +1 more source

Optimization of seminal extracellular vesicle isolation protocols for cancer biomarker analysis using proteomic profiling

Molecular Oncology, EarlyView.
This paper shows that size‐exclusion chromatography and sequential centrifugation applied to seminal plasma enrich for different populations of extracellular vesicles. This may significantly affect the detection and analysis of extracellular vesicle‐associated cancer biomarkers.
Elen Telumyan, Beatriz Martín‐Gracia, Eva Bassols‐Citores, Krizia Sagini, Maria K. Andersen, Tuula A. Nyman, May‐Britt Tessem, Morten B. Rye, Alicia Llorente   +8 more
wiley   +1 more source

Widespread male-female expression imbalance of X-linked genes across phrynosomatid lizards. [PDF]

Mol Biol Evol
Hale MD, de Mello PLH, Nondorf DT, Robinson CD, John-Alder HB, Cox CL, Cox RM.   +6 more
europepmc   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

Molecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

Pervasive Positive Selection on X-linked Ampliconic Genes in Primates. [PDF]

Genome Biol Evol
Diepeveen E, Riera Bellés M, Heide Schierup M.   +2 more
europepmc   +1 more source

X Linked Mental Retardation [PDF]

Australian Journal of Mental Retardation, 1970
openaire   +2 more sources

UiO‐66 metal–organic frameworks in biomedicine: From structural tunability to bioimaging, photodiagnostics, and photodynamic cancer therapy

FEBS Open Bio, EarlyView.
UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.
Veronika Huntošová, Grigorii Rakhalskii, Miroslav Almáši   +2 more
wiley   +1 more source